WO2016095877A1 - Substituted 2-(2-phenylhydrazinyl)pyrazine, process for its preparation, its use and a pharmaceutical composition containing the same - Google Patents

Substituted 2-(2-phenylhydrazinyl)pyrazine, process for its preparation, its use and a pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2016095877A1
WO2016095877A1 PCT/CZ2015/000127 CZ2015000127W WO2016095877A1 WO 2016095877 A1 WO2016095877 A1 WO 2016095877A1 CZ 2015000127 W CZ2015000127 W CZ 2015000127W WO 2016095877 A1 WO2016095877 A1 WO 2016095877A1
Authority
WO
WIPO (PCT)
Prior art keywords
general formula
substituted
phenylhydrazinyl
pyrazines
drug
Prior art date
Application number
PCT/CZ2015/000127
Other languages
English (en)
French (fr)
Inventor
Martin DOLEZAL
Jan Zitko
Ondrej JANDOUREK
Barbora SERVUSOVA-VANASKOVA
Original Assignee
Univerzita Karlova V Praze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univerzita Karlova V Praze filed Critical Univerzita Karlova V Praze
Publication of WO2016095877A1 publication Critical patent/WO2016095877A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to novel compounds based on substituted phenymydrazinyl- pyrazines, processes for their preparation, and their use as antituberculous drugs and pharmaceutical preparations containing them.
  • Substituted pyrazine derivatives belong to compounds having significant biological activity, they are used as essential drugs (Miniyar P.B., Murumkar P.R., Patil P.S., et al.: Mini Rev. Med. Chem. 13, 1607-25, 2013; Ferreira S.B., Kaiser C.R. Exp. Opin. Ther. Patents 22, 1033- 51, 2012).
  • Tuberculosis caused by Mycobacterium tuberculosis complex (MTB), has for many years belonged to the most widespread infectious diseases in the world. Its incidence and mortality has so far failed to reduce despite existing antituberculotic therapy (World Health Organization, Stop TB Partnership. Tuberculosis Global Facts 2014). The reason is the emergence and development of increasingly resistant forms of the disease agent and co- infection with HIV, the incidence in the Czech Republic is increasing (tJstav zdravotnickych informaci a statholic CR; Tuberkuloza a respiracni nemoci 2012, Prha UZIS, 2013, 111pp.).
  • the most important first line anti-tuberculosis drugs include pyrazinamide (PZA).
  • PZA pyrazinamide
  • PZA does not act by a single mechanism, but we recognize still new ways of its action: a) PZA is a prodrug, which is converted with the enzyme nikotinamidase/pyrazinamidase (PncA) to the pyrazinoic acid (POA), as its active form. There is an accumulation of POA and intracellular acidification (Dolezal M., Kesetovic D., Zitko J. Curr. Pharm. Design, 2011, vol. 17, no. 32, p. 3506-3514). This disturbance leads to influencing the activity of enzymatic systems and disrupting the processes that are dependent on the pH gradient at the interface organelle / cytoplasmic compartment (Zhang H., et al.
  • POA acts by inhibiting protein and RNA synthesis, serine uptake, disruption of membrane potential in the acidic pH (Wright H.T., Reynolds K.A. Curr. Opin. Microbiol. 10, 447-453, 2007);
  • PZA influences RpsA - an enzyme system responsible for regulating biological processes, hcluding cell adhesion, migration and differentiation (Zimic M, et al. Microb. Drug Resist. 18, 372-375, 2012; Sayahi H. ⁇ et al. Chemistry & Biodiversity 9, 2582-2596, 2012).
  • PZA inhibits tra «s-translation, which is a process to prevent the creation of non-functional proteins, and is associated with stress survival, virulence and recovery of nutrient starvation (Shi W., Zhang X., Jiang X., et al. Science 333, 1630-1632, 2011); c) estimated competition of PZA (and 5-chloro-pyrazine-2-carboxamide) with NADPH for binding to the complex FAS I (Fatty Acid Synthase). The synthesis of mycolic acids, which are part of the cell wall of mycobacteria, is inhibited. Also POA is binding to FAS I, but in different location of the enzyme (Zimic M, et al. Microb.
  • FAS I is the primary goal of the pyrazinamide derivatives, including 5-chloropyrazinamide, which also inhibits FAS complex II.
  • FAS I is involved in the synthesis of short chain-mycolic acids, FAS II mediates the synthesis of long chain-mycolic acids.
  • FAD II is the enoyl- ACP reductase (Ngo S.C., et al. Antimicrob. Agents Chemother. 51, 2430-2435, 2007).
  • ATs which would act against MDR-TB strains, or against latent forms of TB. They must be structurally novel compounds which act by novel mechanisms other than the currently used AT, or with an improved pharmacokinetic profile.
  • New potential ATs which are now in preclinical and clinical stage of development, are often substances which contain a nitro moiety in their molecule. Relevant examples include the nitroimidazoles pretomanid, OPC-67683 and delamanid.
  • Another promising group of AT are oxazolidinones, for example linezolid and Vozolid, containing, inter alia, the carboxamide functional moiety (Matthias Stehr M., Elamin A.A., Singh M. Curr. Top. Med. Chem. 14, 110-129, 2014).
  • nitro or carboxamide moieties have proved essential for the antimycobacterial activity, but the mechanisms of action were different for each other (Matthias Stehr M., Elamin A.A., Singh M. Curr. Top. Med. Chem. 14, 110-129, 2014).
  • the pyrazinecarboxamide motif can be found in a wide range of modern drugs such as the antineoplastic agent bortezomib (Palle Raghavendracharyulu Venkata, Kadaboina Rajasekhar, Murki Veerendeer et al., Bortezomib and proces for producing same.
  • a PZA fragment is also contained in a large number of drugs which are in the clinical trial phase, for example pyrazine derivatives patented as kinase inhibitors (Charrier J.D., Durrant S.J., Kay D., et al. Compounds useful as inhibitors of ATR kinase; US2014113005 (2014); Song Y., Xu Q., Jia Z., et al. Preparation of pyrazine derivatives for use as Syk kinase activity inhibitors. US20130131040 (2013); Boyle R.G., Boyce R.J.
  • microwave synthesis methods Over the past decades, methods of microwave synthesis methods and their applications suitable for the development of new drugs have got the forefront of interest of pharmaceutical chemists. These reactions usually provide a higher yield, require significantly shorter reaction time, and reduce the consumption of solvents compared to conventional methods of organic synthesis. In some cases, the desired products can be obtained only by using a microwave synthesis. Advantages of these reactions can be explained by the interaction of microwaves and molecules; the possibility of reaching a temperature greater than the boiling point of the solvent at atmospheric pressure (in a sealed system) is also very advantageous (Hayes B.L. Microwave Synthesis: Chemistry at the Speed of Light; CEM Publishing: Matthews, NC, USA, 2002; De la Hoz A., Diaz-Ortiz A., Moreno A.
  • microwaves in organic synthesis Thermal and non-thermal microwave effects. Chem. Soc. Rev. 34, 164-178, 2005).
  • microwaves act directly on the molecules present in the reaction mixture and heating is hence not dependent on the thermal conductivity of the container, unlike in classical heating.
  • the transmission of energy from the microwave heating to the substance proceeds by two basic mechanisms, either by dipole rotation, or by ion conductivity. Dipole rotation is an interaction of the spin at which polar molecules attempt to align with rapidly changing electric field of the microwaves. This rotational motion of molecules results in energy transfer. The second way is to transmit energy through the ion conduction.
  • the important characteristics of used solvents include their polarity, the rule for which is that the more polar solvent, the higher the ability to interact with microwaves will be. Even solvents having a low boiling point can be used in this synthesis because the microwave energy reaches and exceeds the boiling point of most of solvents in a few seconds. Using of pressurized reaction vessels further ensures recovery of solvents with a low boiling point. Another important factor in selecting the solvent is how efficiently the solvent molecules interact with microwaves and convert the microwave energy into thermal energy. The microwave synthesis can be applied even in systems without using any solvent. There are three main types of reactions without solvent: reaction mixtures adsorbed on mineral oxides, reactions of a phase transfer catalyst and a clean reactions (Hayes B.L. Microwave Synthesis: Chemistry at the Speed of Light; CEM Publishing: Matthews, NC, USA, 2002).
  • the compound 5-chloro-6-methyl-pyrazine-2,3-dicarbonitrile (II) was used in the past for the preparation of a series of substituted 5-benzylamino-6-memylpyrazme-2,3-dicarborutriles; the obtained products did not show significant biological properties in the tests (Jandourek, O.; Dolezal, M.; Paterova, P.; Kubicek, V.; Pesko, M.; unes, J.; Coffey, A.; Guo, J.; ralova, . Molecules 19, 651-671,2014).
  • the compound 3-cWoropyrazme-2-carboxarrude (III) was used in the past for the preparation of a series of substituted 3-(alkylamino)pyrazine-2- carboxamides; the products obtained did not show significant biological properties in the assays (Jandourek, O.; Dolezal, M.; Kunes, J.; Kubicek, V.; Paterova, P.; Pesko, M.; Buchta, V.; Kralova, K.; Zitko, J. Molecules 19, 9318-9338, 2014).
  • the invention relates to novel substituted 2-(2-phenymydrazinyl)pyrazine of the general formula I
  • each R 1 , R 2 is independently H or CN; R 3 is CH 3 or CONH 2 ; each R 4 , R s , R 6 , R 7 , R 8 is independently H, CI, or N0 2 .
  • Another object of the invention is a method for preparing of a substituted 2-(2- phenylhydrazinyl)pyrazine of general formula I, consisting in that the substituted chloropyrazine of general formula
  • each R 4 , R 5 , R 6 , R 7 , R 8 is independently H, CI, or N0 2 , in a polar solvent, under the conditions of microwave synthesis to form a substituted phenymydrazinylpyrazine of general formula I.
  • Another object of the invention relates to the use of the above mentioned substituted 2-(2- fenylhydrazinyl)pyrazine of the formula I according to the invention for use as an antituberculotic against Mycobacterium tuberculosis and against its atypical strains (mycobacteriosis pathogens), including pathogenic strains isolated from the sick patients.
  • All compounds of the general formula I contain, in their molecule, the hydrazino group, but their toxicity in the tests carried out is very low. These substances are exceptional with by their low toxicity since the hydrazine group in the molecule of a drug usually bears higher toxicity or irritation. Based on current knowledge of pharmaceutical chemistry such substitution in the field of synthesis of new promising drugs previously has always been considered undesirable.
  • the essence of the invention consists is a combination of the six-membered heterocycle pyrazine and an aromatic part, linked each other with a linking hydrazine bridge.
  • the heteroaromatic ring is substituted with a carboxamide or carbonitrile moieties, while the aromatic ring is unsubstituted, or substituted with nitro groups or chlorine atoms in various positions.
  • the starting compounds II and III are accessible by conventional methods of organic synthesis (Takematsu T. f Segawa H., Miura, T. et al. A. 2,3-Dicyanopyrazines. USP4259489, 1981; Dlabal K., Palat K., Lycka A., Odlerova Z. Synthesis and 1H- and 13 C-NMR spectra of sulfur derivatives of pyrazine derived from amidation product of 2-chloropyrazine and 6- chloro-2-pyrazinecarbonitrile. Tuberculostatic activity. Collect. Czechoslov. Chem. Commun. 55, 2493-2500, 1990).
  • Microwave Synthesis Chemistry at the Speed of Light; CEM Publishing: Matthews, NC, USA, 2002; De la Hoz A., Diaz-Ortiz A., Moreno A. Microwaves in organic synthesis. Thermal and non- thermal microwave effects. Chem. Soc. Rev. 34, 164-178, 2005).
  • the apparatus used is equipped with a so-called focused field, which is advantageous since the microwaves are aimed directly to the reaction mixture placed in a waveguide.
  • Another positive aspect of the method used is also time, energy and solvents saving.
  • the prepared compounds of general formula I have been evaluated in vitro against the strains of M. kansasii 235/80, M. avium 80/72, M. avium 152/73 and M. tuberculosis H37Rv using a fluid Sula's semisynthetic medium (Trios, Prague, Czech Republic) by the microdilution method in comparison with pyrazinamide (PZA) at pH 5.6.
  • the tested compounds were dissolved in dimethylsulfoxide (DMSO) and diluted with the medium to final concentrations of 100, 50, 25, 12,5, 6,25, 3,125 and 1,563 ⁇ g mL. The results were read after two or three weeks. Pyrazinamide (PZA) was used as the standard. The results are shown in Table 1.
  • Results indicate high antimycobacterial activity, for all tested compounds of formula I it was 2-16x higher than that of the used standard PZA. High activity was discovered against M. ⁇ s sii for compounds 1-5 of general formula I and against M. avium in the case of compounds 2-4 of general formula I.
  • pH / buffer 7.0 / MOPS (0,165 M)
  • the prepared derivatives corresponding to the general formula I were also tested for antiviral activity at Rega Institute for Medical Research, KathoUeke Universiteit, Leuven, Belgium (Prof. Dr. Lieve Naesens and co-workers).
  • the viral infections against which efficacy was evaluated included: Influenza virus A ( ⁇ ; H3N2) and B, Herpes simplex virus- 1 and -2, Vesicular stomatitis virus, Vaccinia virus, Parainfluenza-3 virus, Reovirus-1, Sindbisvirus, Coxsackie virus B4, Punta Toro virus, Respiratory syncytial virus, Feline corona virus, Feline herpes virus.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above.
  • TLC Thin Layer Chromatography
  • Elemental analyses were measured with an EA 1110 CHNS Analyzer (Fisons Instruments S. p. A., Carlo Erba, Milano, Italy). All measured values are given in percent.
  • Log k calculated from the capacity factor k, is used as the Upophilicity index converted to log P scale. Values of log P and Clog P were calculated with the PC programme CS ChemBioDraw Ultra 13.0 (CambridgeSoft, Cambridge, MA, USA).
  • Compound 1 is prepared by reaction of phenylhydrazine (3 mmol) with 5-chloro-6- memylpyrazine-2,3-dicarbomtrile (II, 1 mmol) in 3 mL of methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140°C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 1 was isolated and purified by column chromatography on silica gel (mobile phase: hexane / ethyl acetate 1:1), yield 29%. Analytical data for compound 1: Brown-red crystalline solid; Mp.
  • Compound 2 is prepared by reaction of 3-chlorophenylhydrazine (3 mmol) with 5-chloro-6- methylpyrazine-2,3-dicarbonitrile (II, 1 mmol) in 3 mL of methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140°C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 2 was isolated and purified by column chromatography on silica gel (mobile phase: hexane / ethyl acetate 1:1), yield 65%. Analytical data for compound 2: Green-brown crystalline solid; Mp.
  • Compound 3 is prepared by reaction of 2-chlorophenylhydrazine (3 mmol) with 5-chloro-6- methylpyrazine-2, 3 -dicarbonitrile (II, 1 mmol) in 3 mL of methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140°C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 3 was isolated and purified by column chromatography on silica gel (mobile phase: hexane / ethyl acetate 1:1), yield 67%. Analytical data for compound 3: Green-brown crystalline solid; Mp.
  • Compound 4 is prepared by reaction of 4-chlorophenylhydrazine (3 mmol) with 5-chloro-6- memylpyrazine-2,3-dicarbonitrile (II, 1 mmol) in 3 mL of methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140°C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 4 was isolated and purified by column chromatography on silica gel (mobile phase: hexane / ethyl acetate 1: 1), yield 21%. Analytical data for compound 4: Light-brown crystalline solid; Mp.
  • Compound 5 is prepared by reaction of 2-nitrophenylhydrazine (3 mmol) with 5-chloro-6- memylpyrazine-2,3-dicarbonitrile (II, 1 mmol) in 3 mL of methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140°C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 5 was isolated and purified by column chromatography on silica gel (mobile phase; hexane / ethyl acetate 1:1), yield 38%. Analytical data for compound 5: Dark-brown crystalline solid; Mp.
  • Compound 10 is prepared by reaction of 2-nitrophen .hydrazine (3 mmol) with 3- chloropyrazine-2-carboxamide (III, 1 mmol) in 3 mL methanol and pyridine (1 mmol). The reaction is performed in a microwave reactor at the temperature 140 °C, pressure 15 kPa and an output of 120 W during 30 min. After completing the reaction, product 10 was ' isolated and purified by column chromatography on silica gel (mobile phase: hexane / ethyl acetate 1:1), yield 17%. Analytical data for compound 10: Red-braun crystalline solid; Mp.
  • Example 11 (content of the active ingredient 100 mg):
  • Example 12 (content of the active ingredient 200 mg):
  • Example 13 (content of the active ingredient 300 mg):
  • Example 14 (content of the active ingredient 400 mg):
  • Example 15 (content of the active ingredient 500 mg):
  • the active ingredient is mixed with the individual ingredients and the tableting blend is compressed in a tablet machine in the usual manner.
  • Example 16 (content of the active ingredient 100 mg):
  • Example 17 (content of the active ingredient 200 mg :
  • Example 18 (content of the active ingredient 300 mg):
  • Example 19 (content of the active ingredient 400 mg):
  • Example 16 (content of the active ingredient 500 mg):
  • the active ingredient is gradually mixed with lactose, potato starch, the mixture is granulated in an aqueous solution of povidone, the dried granulate is mixed with sodium carboxymethyl starch, magnesium stearate and talc and the resulting blend is compressed in a tablet machine in the usual way.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CZ2015/000127 2014-12-17 2015-10-26 Substituted 2-(2-phenylhydrazinyl)pyrazine, process for its preparation, its use and a pharmaceutical composition containing the same WO2016095877A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2014-925A CZ306322B6 (cs) 2014-12-17 2014-12-17 Substituovaný 2-(2-fenylhydrazinyl)pyrazin, způsob jeho přípravy, jeho použití a farmaceutický přípravek ho obsahující
CZPV2014-925 2014-12-17

Publications (1)

Publication Number Publication Date
WO2016095877A1 true WO2016095877A1 (en) 2016-06-23

Family

ID=54608210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2015/000127 WO2016095877A1 (en) 2014-12-17 2015-10-26 Substituted 2-(2-phenylhydrazinyl)pyrazine, process for its preparation, its use and a pharmaceutical composition containing the same

Country Status (2)

Country Link
CZ (1) CZ306322B6 (cs)
WO (1) WO2016095877A1 (cs)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259489A (en) 1977-12-22 1981-03-31 Kyowa Gas Chemical Industry Co. Ltd. 2,3-Dicyanopyrazines
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
US20100226597A1 (en) 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
US20130131040A1 (en) 2011-11-23 2013-05-23 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2013072502A1 (en) 2011-11-16 2013-05-23 Sentinel Oncology Limited Pharmaceutically active pyrazine derivatives
US20140113005A1 (en) 2008-11-10 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149279A (en) * 1934-07-07 1939-03-07 Merck & Co Inc Derivatives of pyrazine carboxylic acid and processes for their production
US6329378B1 (en) * 1999-02-10 2001-12-11 Anadys Pharmaceuticals, Inc. Hydrazone, hydrazine and thiosemicarbazone derivatives as antifungal agents
CN101693696B (zh) * 2009-10-17 2011-12-14 西北师范大学 含吡嗪肼的酰基硫脲类化合物及其制备和应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259489A (en) 1977-12-22 1981-03-31 Kyowa Gas Chemical Industry Co. Ltd. 2,3-Dicyanopyrazines
US5185450A (en) 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
US20100226597A1 (en) 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
US20140113005A1 (en) 2008-11-10 2014-04-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013068755A1 (en) 2011-11-09 2013-05-16 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
AU2012335409A1 (en) 2011-11-09 2014-04-17 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
WO2013072502A1 (en) 2011-11-16 2013-05-23 Sentinel Oncology Limited Pharmaceutically active pyrazine derivatives
US20130131040A1 (en) 2011-11-23 2013-05-23 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Ustav zdravotnickych informaci a statistiky CR", TUBERKULOZA A RESPIRACNI NEMOCI 2012, 2013, pages 111
CRANDELL R.A.; FABRICANT C.G.; NELSON-REES W.A, IN VITRO, vol. 9, 1973, pages 176 - 185
DE LA HOZ A.; DIAZ-ORTIZ A.; MORENO A.: "Microwaves in organic synthesis. Thermal and non-thermal microwave effects", CHEM. SOC. REV., vol. 34, 2005, pages 164 - 178
DLABAL K.; PALAT K.; LYCKA A.; ODLEROVA Z.: "Synthesis and H- and C-NMR spectra of sulfur derivatives of pyrazine derived from amidation product of 2-chloropyrazine arid 6-chloro-2-pyrazinecarbonitrile. Tuberculostatic activity", COLLECT. CZECHOSLOV. CHEM. COMMUN., vol. 55, 1990, pages 2493 - 2500
DOLEZAL M.; KESETOVIC D.; ZITKO J., CURR.. PHARM. DESIGN, vol. 17, no. 32, 2011, pages 3506 - 3514
FERREIRA S.B.; KAISER C.R., EXP. OPIN. THER. PATENTS, vol. 22, 2012, pages 1033 - 51
FURUTA Y; TAKAHASHI K; SHIRAKIB K ET AL.: "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections", ANTIVIRAL RES., vol. 82, 2009, pages 95 - 102
HAYES B.L.: "Microwave Synthesis: Chemistry at the Speed of Light", 2002, CEM PUBLISHING
JANDOUREK, O.; DOLEZAL, M.; KUNES, J.; KUBICEK, V.; PATEROVA, P.; PESKO, M.; BUCHTA, V.; KRALOVA, K.; ZITKO, J., MOLECULES, vol. 19, 2014, pages 9318 - 9338
JANDOUREK, O.; DOLEZAL, M.; PATEROVA, P.; KUBICEK, V.; PESKO, M.; KUNES, J.; COFFEY, A.; GUO, J.; KRALOVA, K., MOLECULES, vol. 19, 2014, pages 651 - 671
LIDSTROM P.; TIERNEY J.; WATHEY B.; WESTMAN J.: "Microwave assisted organic synthesis - a review", TETRAHEDRON, vol. 57, 2001, pages 9225 - 9283
MAKAM PARAMESHWAR ET AL: "2-(2-Hydrazinyl)thiazole derivatives: Design, synthesis andin vitroantimycobacterial studies", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 69, 1 July 2007 (2007-07-01), pages 564 - 576, XP028762830, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2013.08.054 *
MATTHIAS STEHR M.; ELAMIN A.A.; SINGH M., CURR. TOP. MED. CHEM., vol. 14, 2014, pages 110 - 129
MINIYAR P.B.; MURUMKAR P.R.; PATIL P.S. ET AL., MINI REV. MED. CHEM., vol. 13, 2013, pages 1607 - 25
NGO S.C. ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 51, 2007, pages 2430 - 2435
SAYAHI H. ET AL., CHEMISTRY & BIODIVERSITY, vol. 9, 2012, pages 2582 - 2596
SHI W.; ZHANG X.; JIANG X. ET AL., SCIENCE, vol. 333, 2011, pages 1630 - 1632
SILVANA C NGO ET AL: "Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs", vol. 51, no. 7, 1 July 2007 (2007-07-01), pages 2430 - 2435, XP002698058, ISSN: 0066-4804, Retrieved from the Internet <URL:http://aac.asm.org/content/51/7/2430> [retrieved on 20070507], DOI: 10.1128/AAC.01458-06 *
WRIGHT H.T.; REYNOLDS K.A., CURR. OPIN. MICROBIOL., vol. 10, 2007, pages 447 - 453
ZEUZEM S.; ANDREONE P.; POL S. ET AL.: "Telaprevir for Retreatment of HCV Infection", NEW ENGL. J. MED., vol. 25, 2011, pages 2417 - 28
ZHANG H. ET AL., THE FEBS JOURNAL, vol. 275, 2008, pages 753 - 762
ZIMIC M. ET AL., MICROB. DRUG RESIST., vol. 18, 2012, pages 372 - 375

Also Published As

Publication number Publication date
CZ306322B6 (cs) 2016-11-30
CZ2014925A3 (cs) 2016-06-29

Similar Documents

Publication Publication Date Title
Thakkar et al. Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities
Hua et al. Studies on the novel pyridine sulfide containing SDH based heterocyclic amide fungicide
Tian et al. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5, 7-disubstituted pyrazolo [1, 5-a] pyrimidine derivatives
Wang et al. Synthesis and biological evaluation of benzofuroxan derivatives as fungicides against phytopathogenic fungi
Ramadan et al. Synthesis and anti H5N1 activities of some novel fused heterocycles bearing pyrazolyl moiety
Gomez et al. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase
JP2019500323A (ja) リジン特異的デメチラーゼ−１の阻害剤を含む組成物
US8314085B2 (en) Agent for overcoming resistance to anti-cancer agent
Ahmed et al. 1, 2, 4-Triazolo-[1, 5-a] pyridine HIF prolylhydroxylase domain-1 (PHD-1) inhibitors with a novel monodentate binding interaction
CN101583622A (zh) 用于破坏与泛素化相关的酶的相互作用的抑制剂和其应用
Nazreen Design, synthesis, and molecular docking studies of thiazolidinediones as PPAR‐γ agonists and thymidylate synthase inhibitors
CN112142675B (zh) 一种作为jak激酶抑制剂的小分子化合物及其用途
Wilson et al. Novel antitubercular 6-dialkylaminopyrimidine carboxamides from phenotypic whole-cell high throughput screening of a softfocus library: structure–activity relationship and target identification studies
Khonde et al. 1, 3-Diarylpyrazolyl-acylsulfonamides as potent anti-tuberculosis agents targeting cell wall biosynthesis in Mycobacterium tuberculosis
Khan et al. Synthesis, biological screening, in silico study and fingerprint applications of novel 1, 2, 4‐triazole derivatives
Ceylan Synthesis and biological evaluation of new Mannich and Schiff bases containing 1, 2, 4-triazole and 1, 3, 4-oxadiazole nucleus
Degorce et al. Discovery of a series of 5-azaquinazolines as orally efficacious IRAK4 inhibitors targeting MyD88L265P mutant diffuse large B cell lymphoma
Rai et al. Synthesis and Anti‐HIV Activity of 4‐(Naphthalen‐1‐yl)‐1, 2, 5‐thiadiazol‐3‐hydroxyl Derivatives
Wang et al. Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach
Kummari et al. Design and synthesis of 1, 2, 3-triazole–etodolac hybrids as potent anticancer molecules
Santoso et al. Synthesis and investigation of phthalazinones as antitubercular agents
Li et al. Arylazolyl (azinyl) thioacetanilides: part 19: discovery of novel substituted Imidazo [4, 5‐b] pyridin‐2‐ylthioacetanilides as potent HIV NNRTIs via a structure‐based bioisosterism approach
Reddy et al. Imidazole‐Oxadiazole Hybrid as Potential Antimicrobial Agents: Design, Synthesis, Drug–Likeness, Pharmacophore and Molecular Docking Study
Li et al. Arylazolyl (azinyl) thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors
Nandikolla et al. Design, synthesis and biological evaluation of phenanthridine amide and 1, 2, 3-triazole analogues against Mycobacterium tuberculosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15797581

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15797581

Country of ref document: EP

Kind code of ref document: A1